AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01424345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjustment of immunosuppressant dosages
Description: adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results
Study NCT01424345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjustment of the dosages of immunosuppressants
Description: adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab
Study NCT02516202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vagifem
Description: One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.
Study NCT02516202 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Replens
Description: 2.5 gm to be applied vaginally every 3 days over 12 weeks.
Study NCT02062385 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to V260
Description: Placebo control
Study NCT02062385 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: OPV
Description: Oral poliovirus vaccine administered according to the standard of care
Study NCT01119092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grade IV AP joint mobilizations
Description: 3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
Study NCT01065701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine is given as premedication prior to induction of anesthesia
Study NCT02062385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPV
Description: Oral poliovirus vaccine administered according to the standard of care
Study NCT02062385 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DTaP
Description: Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
Study NCT03138161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedinis an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
Study NCT03138161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for (1) treatment of unresectable or metastatic melanoma, and (2) adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
Study NCT03138161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-medicated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
Study NCT01499966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plaster of Paris/ Tubigrip
Description: After informed consent was obtained the patients were randomized such that each patient was allocated to use either a Tubigrip (Group A) or Plaster of Paris (Group B). The standardized treatment in the form of RICE (Rest, Ice, Compression and Elevation) protocol was given to all patients. The Patients were randomized using the Block randomization. One hundred and twenty six white papers were taken and TG for Tubigrip and POP for Plaster of Paris were written and the patients were allowed to pick the envelope of their choice. The authors were blinded till the opening of the envelope by the patients. Patient's usage of analgesia in form of Paracetamol was specifically noted. The patients in TG group receive the Tubigrip treatment and the patients in POP group were given a below knee plaster cast. Patients were instructed to follow up at 2 weeks and then at 6 weeks
Study NCT02062385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP
Description: Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
Study NCT02516202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Dispensed in visually identical bottle and tablet form to Vagifem.
Study NCT02516202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Dispensed in visually identical bottle and tablet form to Vagifem.
Study NCT02574598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Use on both arms as standard of care.
Study NCT03489460 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Specialized sleep-related message interventions
Description: Over the course of 2 weeks' participants will receive specialized sleep-related message interventions to encourage sleep awareness via the smartphone application.
Study NCT03264807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D2 lymphadenectomy
Description: Subtotal gastrectomy with D2 lymphadenectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) is conventional surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
Study NCT03264807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 and #14v lymphadenectomy
Description: Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and #14v lymphadenectomy is experimental surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
Study NCT04211116 — intervention group
Intervention type: DEVICE
Intervention: Central venous line insertion
Description: Pediatric patients indicated to central venous line insertion
Study NCT02936908 — intervention group
Intervention type: OTHER
Intervention: Ventilatory support
Description: Initiation of mechanical ventilatory support, invasive or non-invasive, Or modification of mechanical ventilatory support (modification of the parameters of the device, change of material, switch from non-invasive to invasive)
Study NCT00770601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study NCT03263260 — intervention group
Intervention type: DEVICE
Intervention: implant
Description: coronary stent implantation
Study NCT02692001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention MealTrain menu
Description: Nutrition education was incorporated using an interpretive traffic light system menu labeling. Dietitians categorized current menu items as green, yellow and red based on fiber, added sugar, saturated fats, and sodium content. A section entitled Eat like a superhero was created to prime children to consider what their potential role models choose, and incorporates descriptive names, suggest sample breakfast, lunch and dinner meals with photographs of portion sizes. Original cartoon female grapes and male broccoli superhero characters were created to employ promotional techniques specifically to promote fruits and vegetable selection for boys and girls.
Study NCT02716181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Атопик Soothing Cream
Description: Topical application of a study cream to involved skin areas twice a day.
Study NCT02716181 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Атопик Soothing Cream
Description: Topical application of a study cream to involved skin areas twice a day.
Study NCT02716181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Topical application of a study placebo cream to involved skin areas twice a day.
Study NCT02716181 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application of a study placebo cream to involved skin areas twice a day.
Study NCT02290977 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Scheduled interval TACE - RT
Description: RT will be administered at 2 weeks after TACE in HCC combined PVTT
Study NCT04651491 — intervention group
Intervention type: DRUG
Intervention: Kagocel
Description: The researchers prescribed antiviral medications, including Kagocel, according to routine clinical practice. Patients who were assigned Kagocel were invited to participate in the study.~Kagocel administration:~1. for children from 3 to 6 years old (n=41): In the first 2 days - 1 tablet 2 times a day, in the next 2 days - 1 tablet once a day. Total for the course of administration 6 tablets within the period of 4 days.~2. for children from 6 years old (n=39) - administered in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. Total for the course of administration 10 tablets within the period of 4 days.
Study NCT02205528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
Study NCT02205528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
Study NCT02205528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
Study NCT02205528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
Study NCT02205528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
Study NCT02205528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0090-2746
Description: NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
Study NCT04140045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water intake
Description: Water intake will be manipulated in both arms to create a hypohydrated state and a euhydrated state, post-exercise
Study NCT02328534 — intervention group
Intervention type: BEHAVIORAL
Intervention: Blastocyst Formation Rate
Description: Embryos developed at Day3 cultures, are continued for Day5 culture tho reach blastocyst stage. The percentage of blastocyst produced from cleaved embryos to be evaluated ar rate.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.
Study NCT02328534 — intervention group
Intervention type: PROCEDURE
Intervention: Blastocyst Rate
Description: Day 5 embryo transfer achieved pregnancy are compared with total embryo transfer cases at Day5.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.~Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.
Study NCT02328534 — intervention group
Intervention type: PROCEDURE
Intervention: Pregnancy Rate
Description: All pregnancy achieved from all ET. Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.
Study NCT04016545 — intervention group
Intervention type: DEVICE
Intervention: Low profile endoprothesis (Navion Medtronic, NBS Low Profile Bolton Terumo)
Description: Aortic aneurysm exclusion through endovascular procedure
Study NCT04220411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR100DP1
Description: topical ointment
Study NCT02466009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
Study NCT02741765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: Subjects will participate in daily sessions of sham-rTMS
Study NCT02741765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real rTMS
Description: Subjects will participate in a combination of rTMS
Study NCT02741765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised aerobic exercise
Study NCT02741765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise
Study NCT01561053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin 5%
Description: Therapeutic plasma exchange with human albumin 5%
Study NCT01561053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin 20%
Description: Low volume plasma exchange with human albumin 5%
Study NCT01561053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunoglobulin
Description: Intravenous human immunoglobulin 5%
Study NCT02516202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Dispensed in visually identical tube and gel form to Replens.
Study NCT02516202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo gel
Description: Dispensed in visually identical tube and gel form to Replens.
Study NCT04059146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Education and Exercise
Description: Participants will be randomly assigned to a pain education group, following biopsychosocial model, or standard of care education, following biomedical model. The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain. Participants will be given weekly online exercises to promote engagement with the material, give individual feedback to participants, and assess understanding. In person sessions with the physical therapist will reinforce self-learning and application to a home exercise program.
Study NCT04059146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education and Exercise
Description: The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage. The videos, handouts, and exercises will be equivalent to the pain education group in terms of time and learning requirements.
Study NCT05175066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: For patients who were candidates to start therapy with anthracycline, bisoprolol was administrated as explained before to determine the effect of this drug on the reduction of anthracycline-induced cardiomyopathy.
Study NCT05175066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets with similar shape and size and color to bisoprolol were given to the patients whom undergone chemotherapy with anthracyclines to compare the effects between two groups.
Study NCT05134207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral carbohydrate solution
Description: Patients in the intervention group; Preop oral carbohydrate solution was ingested orally twice within 10 minutes, as 800 ml at 24:00 the night before the surgery and 400 ml at 06:00 2 hours before the surgery.
Study NCT03467087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myopuls 2000D
Description: Device: Myopuls 2000D (Curatec Services GmBH, 47443 Moers, Germany)
Study NCT03054662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education of patients and caregivers about haemophilia and carriers of haemophilia.
Study NCT03054662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Improve biological diagnosis and follow-up of haemophilia
Description: train the laboratory to the diagnosis ans follow-up un haemophilia
Study NCT03054662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Implement haemostatic non substitutive care of haemophilia
Description: Implement the use of DDAVP and antifibrinolytics in patients with haemophilia and symptomatic carriers
Study NCT00529529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Description: Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
Study NCT00529529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol 50 μg
Description: Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
Study NCT00529529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
Study NCT00529529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
Study NCT00529529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to salmeterol
Description: Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
Study NCT03489460 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GAD
Description: Survey responses will be merged with objective GAD data (sleep time, time in deep sleep, physical activity) which will assist in developing message design formats for message testing.
Study NCT02033720 — intervention group
Intervention type: OTHER
Intervention: No treatment
Description: No therapeutic hypothermia was induced.
Study NCT02033720 — intervention group
Intervention type: OTHER
Intervention: Therapeutic hypothermia
Description: Hypothermia was induced after successful resuscitation from cardiac arrest.
Study NCT01824368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis Procedure (FEC)
Description: The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.~1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.~Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex.
Study NCT04654299 — intervention group
Intervention type: PROCEDURE
Intervention: External biliary stent
Description: The biliary stent consisted of a multi-perforated, natural rubber tube, measuring 3.5 mm in diameter, that we placed transanastomotically, with exteriorization sited at 20 cm utilizing the Witzel jejunostomy approach
Study NCT00422227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept , Methotrexate
Description: * Etanercept: 25 mg twice weekly over 16 weeks, SC~* Methotrexate: > 7.5 mg/week and no more than 25 mg/week, PO
Study NCT00422227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide
Description: * Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~* Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~* Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~* Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily
Study NCT00430703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: body weight support treadmill training
Description: Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
Study NCT01449604 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: stereotactic radiotherapy
Description: Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions